title: Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide.
abstract: OBJECTIVE
  Because dry eye greatly reduces quality of life, this study aimed to examine rebamipide instillation in patients with dry eye and assess the improvement of signs and symptoms as evaluated with the Ocular Surface Disease Index, which is the most popular index and is highly reliable.
  
  
  METHODS
  From June 2013 through January 2014, we examined 50 eyes of 25 patients with dry eye (6 men and 19 woman) at our institution. Dry eye was diagnosed on the basis of the presence of symptoms, tear dynamics, and ocular surface abnormalities according to the Japanese criteria for dry eye. Before being enrolled, all patients underwent ocular surface health assessment, including history interviews, and completed the Ocular Surface Disease Index questionnaire. Patients received 2% rebamipide ophthalmic solution 4 times daily for 4 weeks. Signs and symptoms were analyzed before and 4 weeks after rebamipide administration. Tear dynamics, tear break-up time, and ocular surface abnormalities were measured and compared between before and 4 weeks after rebamipide administration.
  
  
  RESULTS
  Of the 25 patients, 9 had definite dry eye and 16 had probable dry eye. Tear break-up time and the fluorescein staining score significantly improved after 4 weeks. However, no significant change was observed for the Schirmer test I and the lissamine green staining score.
  
  
  CONCLUSIONS
  The administration of 2% rebamipide 4 times daily for 4 weeks improves the signs and symptoms of dry eye and improves patients' quality of life.
authors.affiliation: Department of Ophthalmology, Nippon Medical School.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Igarashi
authors.forename: Miho
authors.initials: M
authors.lastname: Fujita
authors.forename: Yumi
authors.initials: Y
authors.lastname: Yamada
authors.forename: Maika
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Chiaki
authors.initials: C
authors.lastname: Fujimoto
authors.forename: Hisatomo
authors.initials: H
authors.lastname: Takahashi
authors.forename: Toru
authors.initials: T
authors.lastname: Igarashi
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Nakano
authors.forename: Hisaharu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takahashi
mesh_terms: D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D015363:Quinolones / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D009883:Ophthalmic Solutions; D015363:Quinolones; C052785:rebamipide; D000409:Alanine